Krystal Biotech (KRYS) Cost of Revenue (2023 - 2026)

Krystal Biotech has reported Cost of Revenue for 4 years, with the latest figure at $6.4 million in Q2 2026.

• Cost of Revenue for Q2 2026 came in at $6.4 million, down 10.16% year-over-year; the trailing twelve-month figure through Jun 2026 was $23.6 million (down 0.89% YoY), and the FY2025 annual result was $23.0 million, up 14.89% from the prior year.
• Cost of Revenue rose to $6.4 million in Q2 2026, from $6.3 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $7.2 million in Q2 2025 and troughed at $223000.0 in Q3 2023.
• A 4-year average of $4.9 million and a median of $5.5 million in 2024 frame the typical range for Cost of Revenue.
• The widest annual swing landed in 2024, when Cost of Revenue surged 2897.31%; it then sank 36.22% in 2025.
• A 4-year view of Cost of Revenue shows it stood at $2.9 million in 2023, then surged by 72.38% to $4.9 million in 2024, then surged by 33.2% to $6.6 million in 2025, then declined by 2.35% to $6.4 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $6.4 million in Q2 2026, $6.3 million in Q1 2026, and $6.6 million in Q4 2025.